Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 16/20 | 0.48 |
| ▸ | CDK7 | P50613 | 6/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12638839 | 0.93 | CHEK1 (0.47) | CHEK1CDK7FGFR1SRCFGFR2 | |
| SCHEMBL12638840 | 0.91 | CHEK1 (0.46) | CHEK1CDK7FGFR1SRCFGFR2 | |
| SCHEMBL14306666 | 0.91 | CHEK1 (0.48) | CHEK1CDK7FGFR1SRCFGFR2 | |
| SCHEMBL12638845 | 0.90 | CHEK1 (0.46) | CHEK1CDK7FGFR1SRCFGFR2 | |
| SCHEMBL12638833 | 0.89 | CHEK1 (0.49) | CHEK1CDK7FGFR1SRCFGFR2 | |
| SCHEMBL12638841 | 0.86 | CHEK1 (0.48) | CHEK1CDK7FGFR1SRCFGFR2 | |
| SCHEMBL12638835 | 0.84 | CHEK1 (0.47) | CHEK1CDK7FGFR1SRCFGFR2 | |
| SCHEMBL12638843 | 0.84 | CHEK1 (0.49) | CHEK1CDK7 | |
| SCHEMBL12638832 | 0.83 | CHEK1 (0.49) | CHEK1CDK7FGFR1SRCFGFR2 | |
| SCHEMBL12638850 | 0.82 | CHEK1 (0.51) | CHEK1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105427-A1 | DEAZAPURINES AND USES THEREOF | DAUN JANE | 2011-05-05 | — | — | US | disclosed |
| US-7868002-B2 | Deazapurines and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-7868002-B2 | Deazapurines and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-20080103137-A1 | Deazapurines and uses thereof | EISAI CO., LTD. | 2008-05-01 | — | — | US | disclosed |
| US-20080103137-A1 | Deazapurines and uses thereof | EISAI CO., LTD. | 2008-05-01 | — | — | US | disclosed |
| US-7314936-B2 | Deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| US-7314936-B2 | Deazapurines and uses thereof | EISAI CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105427-A1 | DEAZAPURINES AND USES THEREOF | TPMT, CD38, CD2 | CHEK1 1272/4885CDK7 259/4885FGFR1 1445/4885 |
| US-20080103137-A1 | Deazapurines and uses thereof | TPMT, TYMP, ENTPD5 | CHEK1 3404/4885CDK7 214/4885FGFR1 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.